A new review in Molecular Cancer explains how tumor-derived exosomes act as mobile signaling hubs that spread immune ...

As a new 'American Covid' variant fuels a surge in UK hospital admissions, here is what you need to know about the symptoms, ...

Argenx SE (NASDAQ: ARGX ) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for ...

Vaccination not only prevents disease caused by acute infection but also protects against long-term immune-related sequelae ...

Dr. Christina Rahm-created Clean Spirits takes center stage in ROOT's growing focus on proactive wellness, natural glutathione production and patented nutritional innovation ...

We live every day surrounded by various microorganisms, such as bacteria and viruses. Yet, we usually go about our lives ...

A Paris case report describes acute spinal cord injury after CAR T cell therapy, likely a rare spinal manifestation of the ...

Researchers have identified a protein, RD3, that can reverse immune evasion in high-risk neuroblastoma, potentially enhancing ...

Edge Delta today introduced the prod immune system, a telemetry-native AI SRE that continuously understands, investigates, ...

Quantum is working with Thermo Fisher to prepare a Phase 2 trial of Lucid-MS in progressive MS after FDA clearance.

Susquehanna University grads have been awarded grants from the National Institutes of Health and the National Science Foundation.

A blood-cancer treatment that Stanford researchers have spent more than two decades developing has now reached an important milestone. Its first commercial patient has been treated following U.S.